NextPlat Corp — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
NextPlat reported Q2 2026 revenue of $11.9M (21% sequential growth from $9.9M Q1), with net loss reduced 92% year-over-year to $144K (vs. $1.8M in Q2 2025). Gross margin expanded to record 40% (vs. 22% prior year). Healthcare contracted pharmacy revenue surged 136% YoY to $2.2M (driven by 340B contracts and medication fulfillment); e-commerce revenue grew 27% sequentially to $4.1M. Company signed 11 new 340B contracts in H1 2026 and announced intended acquisition of a Pensacola-area pharmacy operation (price undisclosed). Cash position: $11.9M; working capital: $14.2M; no material unsecured debt.
Why this rating
Significant turnaround: losses shrinking rapidly, margins doubling YoY, revenue accelerating. Acquisition signals growth intent. For $11.2M market-cap company, $11.9M quarterly revenue and path to profitability are material trajectory shifts.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.